Top
image credit: Pexels

FDA Advisors Support New Alzheimer’s Drug, Donanemab

June 11, 2024

Via: Drugs.com
Category:

A U.S. Food and Drug Administration advisory panel voted unanimously on Monday to recommend that the benefits of a new drug for Alzheimer’s outweigh its harms, which can include brain swelling and bleeding.

Eli Lilly’s donanemab did slow declines in thinking skills in patients with early-stage Alzheimer’s: Company data showed patients who took donanemab had a 37% lower risk of progression of the disease over 18 months compared to patients who got a placebo.

Read More on Drugs.com